Cutia Therapeutics (HKG:2487) said the Phase II clinical trial of CU-20401 for treating submental adipose accumulation reached its primary endpoint with statistically significant and clinically meaningful outcomes, according to a Friday filing with the Hong Kong bourse.
CU-20401 is a recombinant mutant collagenase aiming to counter obesity, overweight, or other localized adipose accumulation-associated metabolic diseases, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments